Outcomes of Intravenous Tocilizumab Treatment for Refractory Pars Planitis.

Lisa Kongrat Stephen Foster Ploysai Rujkorakarn Michael J Margolis Tate Valerio Yasmin Massoudi Stephen D Anesi Charles Stephen Foster

Published in: Ocular immunology and inflammation (2024)

IV Tocilizumab (TCZ) may represent an effective and safe treatment option for patients diagnosed with pars planitis resistant to conventional immunomodulatory therapy and anti-TNF alpha agents.

Keyphrases

rheumatoid arthritis
end stage renal disease
newly diagnosed
ejection fraction
juvenile idiopathic arthritis
peritoneal dialysis
adipose tissue
skeletal muscle
metabolic syndrome
patient reported outcomes
mesenchymal stem cells
combination therapy